Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
Google Halts UK YouTube TV Measurement Service After Legal Action 
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
Elon Musk Reportedly Eyes June 2026 SpaceX IPO Timed With Planetary Alignment and Birthday 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
The Maire - EuroChem Case: Three Lessons for Global Business 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
NEW YORK, May 17, 2017 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conferences:
- UBS Global Healthcare Conference on May 23, 2017 at 2:30 p.m. Eastern Time
- Jefferies Healthcare Conference on June 8, 2017 at 2:00 p.m. Eastern Time
- Goldman Sachs 38th Annual Healthcare Conference on June 13, 2017 at 11:20 a.m. Pacific Time
Webcast information for these events will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
For more information about Intercept Pharmaceuticals, please contact: Intercept Pharmaceuticals: Mark Vignola +1-646-747-1000 [email protected] Media inquiries: [email protected] Investor inquiries: [email protected]
